Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $22M rose 325.4% year over year, ahead of the -309.6% change in trailing-twelve-month other income / expenses.
Context
- Other income / expenses amounted to 196316.7% of revenue in FY2025, up 170479.0 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +325.4% holds above the trailing-twelve-month pace of -309.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (70.67M) USD
- Year-over-year change
- -548.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (70.67M) | -548.4% |
| FY2024 | 2024-12-31 | 15.76M | +27.4% |
| FY2023 | 2023-12-31 | 12.38M | +214.1% |
| FY2022 | 2022-12-31 | 3.94M | +111.1% |
| FY2021 | 2021-12-31 | (35.44M) | — |
Other Income / Expenses vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -309.6% is the lowest of 10, against a peer median of -46.9%.
- Other income / expenses amounts to 175948.4% of revenue for LYEL, versus a peer median of 39.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46M USD | -3.2% | — | — | |
| LTM Mar 2026 | $7.39M USD | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $6.42M USD | -36.5% | +80.0% | — | |
| LTM Mar 2026 | $6.16M USD | -32.3% | — | 15.9% | |
| LTM Mar 2026 | $3.97M USD | -46.9% | +55.6% | — | |
| LTM Mar 2026 | $2.64M USD | -79.4% | — | 1.2% | |
GNLXGenelux Corporation | LTM Mar 2026 | $1.99M USD | +5.2% | — | 24812.5% |
| LTM Mar 2026 | $1.43M USD | — | -50.1% | 155.2% | |
| LTM Mar 2026 | $1.01M USD | -70.6% | +29.4% | — | |
| LTM Mar 2026 | -CHF 1.47M CHF | -268.3% | — | 39.8% | |
| LTM Mar 2026 | -$54.54M USD | -309.6% | — | 175948.4% | |
| Peer median (excluding LYEL) | — | -46.9% | +55.6% | 39.8% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| Weighted Avg Shares | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
| Weighted Avg Shares (Diluted) | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.